← Human Trials & Peer-Reviewed Studies
Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.
Plain-language guide to PMID 26119844 (2015): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 26119844
- Journal
- Clinical endocrinology
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Foroozanfard F et al. (9 authors)
- DOI
- 10.1111/cen.12840
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
This study was conducted to determine the effects of calcium plus vitamin D supplementation on inflammatory factors and biomarkers of oxidative stress among overweight vitamin D-deficient women with polycystic ovary syndrome (PCOS).
Who Took Part
PubMed indexes the participants as teenagers, young adults and adults, women only.
This randomized double-blind placebo-controlled clinical trial was performed among 104 overweight vitamin D-deficient women diagnosed with PCOS aged 18-40 years.
Participants were randomly divided into four groups.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Fasting blood samples were taken at baseline and 8 weeks after intervention to measure inflammatory factors and biomarkers of oxidative stress.
What Was Measured
Topics PubMed links to this paper include Antioxidants, Biomarkers, C-Reactive Protein, Calcium, Dietary Supplements, Glutathione and Overweight.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (Clinical endocrinology), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.